![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 2-aminocarbonyl-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)-pentyl)-1-piperazineacetamide
2. R 75 231
3. R 75231
4. R 88 016
5. R 88016
6. R-75231
7. R-88016
8. R75231
1. 120770-34-5
2. R-75231
3. (s)-draflazine
4. 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide
5. R 75231
6. R75231
7. 0y25dt968y
8. R-70380
9. Draflazinum
10. R70380
11. Draflazina
12. Draflazinum [inn-latin]
13. Draflazina [inn-spanish]
14. Draflazine [usan:inn:ban]
15. Unii-0y25dt968y
16. Draflazine [inn]
17. Draflazine (usan/inn)
18. Draflazine [usan]
19. (+-)-4'-amino-4-(5,5-bis(p-fluorophenyl)pentyl)-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide
20. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-
21. Schembl215826
22. Gtpl4590
23. Chembl1628717
24. Dtxsid60869655
25. Benzenemethanesulfonylchloride, 2-methyl-
26. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-,(+-)-
27. Db-057830
28. Hy-106841
29. Cs-0026695
30. Ft-0743995
31. D03906
32. Q27077112
33. (+/-)-2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-1-piperazine-acetamide
34. (+/-)-4'-amino-4-(5,5-bis(p-fluorophenyl)pentyl)-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide
35. 1-{[(4-amino-2,6-dichlorophenyl)carbamoyl]methyl}-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide
36. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-, (+/-)-
37. 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-1-piperazineacetamide
Molecular Weight | 604.5 g/mol |
---|---|
Molecular Formula | C30H33Cl2F2N5O2 |
XLogP3 | 5.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 11 |
Exact Mass | 603.1979370 g/mol |
Monoisotopic Mass | 603.1979370 g/mol |
Topological Polar Surface Area | 105 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 810 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)